SG11201403718YA - Method of treating alveolar bone loss through the use of anti-sclerostin antibodies - Google Patents

Method of treating alveolar bone loss through the use of anti-sclerostin antibodies

Info

Publication number
SG11201403718YA
SG11201403718YA SG11201403718YA SG11201403718YA SG11201403718YA SG 11201403718Y A SG11201403718Y A SG 11201403718YA SG 11201403718Y A SG11201403718Y A SG 11201403718YA SG 11201403718Y A SG11201403718Y A SG 11201403718YA SG 11201403718Y A SG11201403718Y A SG 11201403718YA
Authority
SG
Singapore
Prior art keywords
bone loss
alveolar bone
sclerostin antibodies
treating alveolar
treating
Prior art date
Application number
SG11201403718YA
Other languages
English (en)
Inventor
Hua Zhu Ke
Min Liu
William V Giannobile
Original Assignee
Amgen Inc
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47429046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201403718Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Univ Michigan filed Critical Amgen Inc
Publication of SG11201403718YA publication Critical patent/SG11201403718YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201403718YA 2011-12-28 2012-12-11 Method of treating alveolar bone loss through the use of anti-sclerostin antibodies SG11201403718YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161580964P 2011-12-28 2011-12-28
PCT/US2012/068975 WO2013101451A1 (fr) 2011-12-28 2012-12-11 Méthode de traitement d'une perte osseuse alvéolaire au moyen d'anticorps anti-sclérostine

Publications (1)

Publication Number Publication Date
SG11201403718YA true SG11201403718YA (en) 2014-07-30

Family

ID=47429046

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201509629QA SG10201509629QA (en) 2011-12-28 2012-12-11 Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
SG11201403718YA SG11201403718YA (en) 2011-12-28 2012-12-11 Method of treating alveolar bone loss through the use of anti-sclerostin antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201509629QA SG10201509629QA (en) 2011-12-28 2012-12-11 Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies

Country Status (20)

Country Link
US (3) US9657090B2 (fr)
EP (2) EP3712168A3 (fr)
JP (3) JP6363954B2 (fr)
KR (3) KR20190120401A (fr)
CN (2) CN104039828B (fr)
AR (1) AR089509A1 (fr)
AU (3) AU2012362898B2 (fr)
BR (1) BR112014016108A2 (fr)
CA (1) CA2858974A1 (fr)
CL (1) CL2014001719A1 (fr)
EA (2) EA036740B1 (fr)
ES (1) ES2813524T3 (fr)
HK (1) HK1198367A1 (fr)
IL (2) IL232942B (fr)
IN (1) IN2014CN04634A (fr)
MX (1) MX354270B (fr)
SG (2) SG10201509629QA (fr)
TW (3) TW202114733A (fr)
WO (1) WO2013101451A1 (fr)
ZA (1) ZA201404610B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
MX354481B (es) * 2010-10-27 2018-03-07 Amgen Inc Anticuerpos dkk1 y métodos de uso.
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
KR20190120401A (ko) * 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
JP6437914B2 (ja) * 2013-07-19 2018-12-12 株式会社 アクシオン・ジャパン パノラマ画像撮影装置及び同装置で用いる画像診断方法
US10449250B2 (en) * 2015-03-13 2019-10-22 Jiangsu Hengrui Medicine Co., Ltd. Anti-sclerostin antibody, antigen binding fragment and medical use thereof
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN111712573B (zh) * 2018-02-12 2023-10-20 安沛治疗有限公司 针对骨硬化蛋白的适体及其用途
US12062170B2 (en) * 2018-10-30 2024-08-13 Diagnocat Inc System and method for classifying a tooth condition based on landmarked anthropomorphic measurements
US20220122261A1 (en) * 2018-10-30 2022-04-21 Diagnocat Inc. Probabilistic Segmentation of Volumetric Images
EP4125993A4 (fr) * 2020-03-26 2024-04-24 Bone Sci. Bio Ltd. Compositions pharmaceutiques comprenant des peptides amphiphiles et leurs procédés d'utilisation
KR102472582B1 (ko) * 2020-08-20 2022-11-30 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법
KR20230079419A (ko) * 2020-09-28 2023-06-07 안지티아 바이오메디슨즈 리미티드 항-스클레로스틴 구축물 및 이의 용도

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
JPH0647532B2 (ja) * 1983-08-31 1994-06-22 ジ アツプジヨン カンパニ− 歯槽骨吸収の治療
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0542810A1 (fr) 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
EP0554376A4 (en) 1990-10-22 1994-08-24 Fox Chase Cancer Center Dna construct for providing rna therapy
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69229482T2 (de) 1991-04-25 1999-11-18 Chugai Seiyaku K.K., Tokio/Tokyo Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE69535641D1 (de) 1994-04-29 2007-12-27 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
EP0871705A4 (fr) 1995-06-05 2000-01-26 Human Genome Sciences Inc Facteur de croissance humain du type ccn
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
DE69738868D1 (de) 1996-05-22 2008-09-11 Viventia Biotech Inc Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
CA2293632C (fr) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
JP2001512016A (ja) 1997-08-01 2001-08-21 ジェンセット 筋肉およびその他中胚葉組織中で発現される分泌タンパク質の５’ｅｓｔ
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
AU4595399A (en) 1998-06-19 2000-01-10 Mcgill University Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
ATE338120T2 (de) 1998-11-27 2006-09-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2000044777A1 (fr) 1999-01-29 2000-08-03 Imclone Systems Incorporated Anticorps specifiques au kdr et leurs utilisations
ES2332916T3 (es) 1999-06-09 2010-02-15 Genentech Inc Composiciones y metodo para el tratamiento de tumores.
AU4196801A (en) 2000-03-02 2001-09-12 Amgen Inc Chordin-like-2 molecules and uses thereof
EP1290169A2 (fr) 2000-06-01 2003-03-12 Amgen, Inc. Polypeptides a noeud de cystines: molecules "cloaked-2" et leurs utilisations
EP1366156A2 (fr) 2000-06-19 2003-12-03 F. Hoffmann-La Roche Ag Polymorphismes genetiques d'osteolevine
CA2632702A1 (fr) 2000-09-01 2002-03-28 Genentech, Inc. Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (fr) 2001-03-13 2002-09-13 The Minister Of National Defence Clonage, expression, sequencage et amelioration fonctionnelle de l'anticorps monoclonal a fragment variable et a chaine simple dirige contre le virus de l'encephalomyelite equine du venezuela
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
JP4467304B2 (ja) 2001-12-06 2010-05-26 バイオコントロール システムズ，インコーポレイティド サンプル収集および試験システム
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
EP2277522B1 (fr) 2002-03-01 2012-11-21 UCB Manufacturing, Inc. Methodes pour augmenter ou diminuer la densité osseuse et identifier des molécules
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
WO2003106657A2 (fr) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Sequences nucleotidiques et sequences d'acides amines wise/sost
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
CA2504493C (fr) 2002-11-01 2015-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procede de prevention d'infections a partir d'agents de terrorisme biologique avec des oligonucleotides cpg immunostimulateurs
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
BR0317715A (pt) * 2002-12-27 2005-11-22 Angiotech Int Ag Composições e processos de uso de collajolie
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
GB0304030D0 (en) 2003-02-21 2003-03-26 King S College London Teeth
ES2379689T3 (es) 2003-03-14 2012-04-30 Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0324854D0 (en) 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
CA2574881C (fr) 2004-08-04 2013-01-08 Amgen Inc. Anticorps contre dkk-1
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007080129A1 (fr) 2006-01-13 2007-07-19 A Chan Holding B.V. Traitement et diagnostic de densité osseuse anormale
WO2008061013A2 (fr) 2006-11-10 2008-05-22 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
EP2094731A2 (fr) 2006-11-10 2009-09-02 UCB Pharma S.A. Anticorps et diagnostics
ES2666650T3 (es) 2006-12-29 2018-05-07 OstéoQC Inc. Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise
BRPI0807205A2 (pt) 2007-02-02 2014-07-22 Novartis Ag Moduladores de ligantes esclerostina para tratamento de distúrbios relacionados ao osso
EP2131860B1 (fr) 2007-03-20 2013-12-18 Eli Lilly & Company Anticorps antisclérostine
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
AU2008320823B2 (en) 2007-11-02 2013-01-17 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
EP2628486A3 (fr) 2007-12-14 2013-10-30 Amgen, Inc. Procédé de traitement d'une fracture osseuse à l'aide d'anticorps anti-sclérostines
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2010004179A2 (fr) 2008-06-30 2010-01-14 France Telecom Communications cooperatives multicellulaires dans un reseau decentralise
GB0903689D0 (en) 2009-03-03 2009-04-15 Sigmavision Ltd Vehicle tyre measurement
WO2010100179A2 (fr) * 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
WO2010100200A2 (fr) * 2009-03-05 2010-09-10 Novartis Ag Préparation d'anticorps lyophilisée
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
WO2010130830A2 (fr) 2009-05-15 2010-11-18 Ablynx N.V. Séquences d'acides aminés dirigées contre la sclérostine et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies des os
WO2011128424A1 (fr) * 2010-04-16 2011-10-20 Novartis Ag Procédés et compositions pour améliorer l'ostéointégration d'implant
EP2569010B1 (fr) * 2010-05-14 2017-04-12 Amgen, Inc Formulations d'anticorps hautement concentrées
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
MX354481B (es) 2010-10-27 2018-03-07 Amgen Inc Anticuerpos dkk1 y métodos de uso.
KR20190120401A (ko) * 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법

Also Published As

Publication number Publication date
SG10201509629QA (en) 2015-12-30
TWI706787B (zh) 2020-10-11
WO2013101451A1 (fr) 2013-07-04
KR20140116089A (ko) 2014-10-01
CN107126560A (zh) 2017-09-05
US9913900B2 (en) 2018-03-13
IL259939B (en) 2020-05-31
CN104039828A (zh) 2014-09-10
TW202114733A (zh) 2021-04-16
WO2013101451A8 (fr) 2014-06-26
KR20190120401A (ko) 2019-10-23
AU2012362898B2 (en) 2017-11-09
CL2014001719A1 (es) 2014-11-03
KR102033669B1 (ko) 2019-10-18
IL232942B (en) 2018-10-31
AU2018200649A1 (en) 2018-02-15
JP2015504887A (ja) 2015-02-16
EP3712168A3 (fr) 2020-10-14
EP2797953B1 (fr) 2020-06-03
EA202091676A1 (ru) 2021-01-29
AU2012362898A1 (en) 2014-07-24
ZA201404610B (en) 2017-11-29
MX2014007965A (es) 2014-11-25
JP2019031567A (ja) 2019-02-28
HK1198367A1 (en) 2015-04-10
AR089509A1 (es) 2014-08-27
MX354270B (es) 2018-02-21
US20140314776A1 (en) 2014-10-23
US9657090B2 (en) 2017-05-23
CA2858974A1 (fr) 2013-07-04
JP2017214359A (ja) 2017-12-07
ES2813524T3 (es) 2021-03-24
BR112014016108A2 (pt) 2018-09-11
AU2019275548A1 (en) 2020-01-02
IL232942A0 (en) 2014-07-31
EA201491286A1 (ru) 2014-09-30
TW201811364A (zh) 2018-04-01
KR20200056473A (ko) 2020-05-22
IN2014CN04634A (fr) 2015-09-18
US20170281761A1 (en) 2017-10-05
CN104039828B (zh) 2017-07-21
TW201330859A (zh) 2013-08-01
EP2797953A1 (fr) 2014-11-05
IL259939A (en) 2018-07-31
JP6363954B2 (ja) 2018-07-25
EP3712168A2 (fr) 2020-09-23
EA036740B1 (ru) 2020-12-15
US20180169234A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
IL259939B (en) A method for treating alveolar bone loss by using antibodies against sclerostin
IL229582A0 (en) Antibodies against kir for the treatment of inflammatory disorders
EP3494922C0 (fr) Procédé de fabrication de prothèses partielles ou totales
EP2773754A4 (fr) Méthode de traitement
ZA201305972B (en) Method for the preparation of biphephos
GB201110095D0 (en) Method of treatment
EP2748199A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP2684167A4 (fr) Compositions et méthodes utiles dans le traitement de maladies
PT2489670T (pt) Processo para a preparação de compostos de quelatos de aminoácidos, compostos de quelatos de aminoácidos e utilização de compostos de quelatos de aminoácidos
ZA201208172B (en) Methods for the treatment of il-1b related conditions
SG10201505454SA (en) Methods and compositions for treating asthma using anti-il-13 antibodies
EP2755667A4 (fr) Procédé d'amélioration de la repousse et de la quantité des cheveux et des poils
IL232190A0 (en) A method for treating inflammatory diseases by anti-m-csf antibodies
EP2758780A4 (fr) Méthode de traitement de la sclérose en plaques
SG11201400405TA (en) Caninised antibodies and method for the production of same
SI2757878T1 (sl) Postopek za pripravo in nadgradnjo podkev
IL229706A0 (en) A method for treating the effects of a stroke
HK1186986A1 (zh) 治療皮膚病的方法
RS55248B1 (sr) Postupak za biološku kontrolu listeria
RS57395B1 (sr) Postupak za tretman čelika
GB201020045D0 (en) Method for the treatment of biogas
EP2791324A4 (fr) Procédé de traitement
GB201111530D0 (en) Method of treatment
GB201109509D0 (en) Method of treatment
GB201109266D0 (en) Method of treatment